A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH TOSITUMOMAB AND/OR IODINE I 131 TOSITUMOMAB IN STUDIES RIT-I-000, RIT-II-001, RIT-II-002, RIT-II-004, or CP-97-012
Observational
N/A
GSK Clinical Trials, MD
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
BEX104526
NCT00240591
December 2003
June 2010
Name | Location |
---|---|
GSK Clinical Trials Call Center | Hoover, Alabama 35216 |
GSK Clinical Trials Call Center | Chula Vista, California 91911 |
GSK Clinical Trials Call Center | Norwich, Connecticut 06360 |
GSK Clinical Trials Call Center | Washington, District of Columbia 20307-5001 |
GSK Clinical Trials Call Center | Gainesville, Florida 32610 |
GSK Clinical Trials Call Center | Aurora, Illinois 60506 |
GSK Clinical Trials Call Center | Albany, New York 12208 |
GSK Clinical Trials Call Center | Fort Worth, Texas 76104 |
GSK Clinical Trials Call Center | Abingdon, Virginia 24211 |
GSK Clinical Trials Call Center | Olympia, Washington 98506 |
GSK Clinical Trials Call Center | Omaha, Nebraska 68198-7680 |
GSK Clinical Trials Call Center | Ann Arbor, Michigan 48109 |